GLMN (glomulin) is a regulatory inhibitor of cullin-RING ubiquitin ligase (CRL) complexes that functions as a negative regulator of E3 ubiquitin ligase activity 12. Structurally, GLMN adopts a HEAT-like repeat fold that binds the E2-interacting surface of RBX1's RING domain, thereby blocking E2 ubiquitin-conjugating enzyme CDC34 access and preventing CRL-mediated ubiquitination 2. This mechanism inhibits RBX1-mediated neddylation of CUL1 and stabilizes SCF complex components including FBXW7, maintaining proper cellular levels of substrates like CCNE1 and MYC 1. GLMN is essential for normal vascular development 1. Loss-of-function GLMN variants cause glomuvenous malformations, characterized by blue-purple vascular lesions with glomus cell overgrowth 3. Recent evidence identifies GLMN mutations as a genetic subtype of Dowling-Degos disease, an autosomal-dominant pigmentation disorder, where GLMN variants distinctively associate with glomuvenous malformations alongside generalized skin hyperpigmentation 45. Loss of GLMN function increases melanin production through elevated melanosomes and upregulation of tyrosinase, while reducing phosphorylated p70S6K 5. Rare germline GLMN variants may also contribute to blue rubber bleb nevus syndrome via dysregulated mTOR signaling 6.